MedPath

A Within-Subject Randomized Controlled Trial on the Effects of Phenytoin on Social Cognition and Behaviour in Males aged 16 Years and Older with Autism Spectrum Disorders

Phase 2
Recruiting
Conditions
Autism Spectrum Disorder
Mental Health - Autistic spectrum disorders
Registration Number
ACTRN12614000747628
Lead Sponsor
niversity of Sydney
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
20
Inclusion Criteria

Meet DSM-IV-TR criteria for Autistic Disorder, Pervasive Developmental Disorder-Not Otherwise Specified or Asperger’s Disorder

Exclusion Criteria

Severe depression, with suicidal thoughts and/or actions; Severe cardiovascular problems; Kidney or Liver problems; Allergies to barbiturates or any other anticonvulsant medicine; Allergies to foods, preservatives or dyes that may be contained in the syrup; Psychosis; Smoke more than 15 cigarettes a day; Phenytoin hypersensitivity; Pregnancy or lactation; High blood sugar levels

Concomitant medications that exclude participants: lcuronium, antineoplastic agents, amiodarone, amphotericin B, azapropazone, azoles, capecitabine [or its metabolite fluorouracil (5FU)], carbamazepine, ciprofloxacin, chloramphenicol, chlordiazepoxide, chlorpropamide, cimetidine, clopidrogel, clozapine, corticosteroids, coumarin anticoagulants, cyclosporine, diazepam, diazoxide, dicumarol, digitoxin, diltiazem, disulfiram, doxycycline, erythromycin, felbamate, fluconazole, fluorouracil, fluoxetine, folic acid, frusemide, fluvoxamine, glibenclamide, H2-antagonists, halothane, isoniazid, itraconazole, ketoconazole, lamotrigine, methadone, methylphenidate, miconazole, nelfinavir, nicardipine, nimodipine, nifedipine, oestrogens, omeprazole, pancuronium, paroxetine, phenobarbitone, phenothiazines, phenylbutazone, praziquantel, quinidine, reserpine, rifampicin, salicylates, sertraline, sodium valproate, succinimides (ethosuximide, methsuximide, phensuximide), sucralfate, sulfonamides, teniposide, tetracycline, ticlopidine, theophylline, tolbutamide, trazodone, valproic acid, verapamil, vecuronium, vigabatrin, viloxazine; Hypericum perforatum (St John's wort); Antacid preparations containing calcium; Vitamin D

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improved social cognition as assessed by the Eye-Gaze Movie Scene Task - duration (total milliseconds spent fixating on the face region) and fixation count (number of times a participant fixated toward a face region).[45 minutes after each single dose administration];Improved accuracy and speed of identification of the correct emotion from faces as assessed by the Reading the Mind in the Eyes Test (RMET) and the Speeded Face Expression Recognition Task.[45 minutes after each single dose administration];Increased Heart Rate Variability assessed by the Polar RS800CX heart rate monitoring system[45 minutes after each single dose administration]
Secondary Outcome Measures
NameTimeMethod
Improved capacity to correctly respond to social cues as assessed by the Social Ball-tossing Game. [45 minutes after each single dose administration]
© Copyright 2025. All Rights Reserved by MedPath